Jove
Visualize
Contact Us

Related Experiment Videos

Resiquimod 3M.

Taff Jones1

  • 1ID Biomedical Corp of Quebec, 7150 Frederick Banting, Suite 200, Ville St-Laurent, Quebec H4S 2A1, Canada. tjones@intellivax.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 3, 2003
PubMed
Summary
This summary is machine-generated.

Resiquimod, an immunomodulator, is in Phase III trials for topical herpes simplex virus (HSV) treatment. Commercialization with Eli Lilly is anticipated for 2004-2005.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Vaccine·2012
Same author

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

PloS one·2010
Same author

Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000)·2010
Same author

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

Current opinion in molecular therapeutics·2009
Same author

IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.

Current opinion in molecular therapeutics·2009
Same author

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Current opinion in molecular therapeutics·2008
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Immunology
  • Virology
  • Dermatology

Background:

  • 3M Pharmaceuticals is developing resiquimod, a topical immunomodulator.
  • Resiquimod is being investigated for treating herpes simplex virus (HSV) infections.

Purpose of the Study:

  • To evaluate the efficacy of topical resiquimod in treating HSV infections.
  • To assess resiquimod's potential as a treatment for other viral infections, eczema, and as a vaccine adjuvant.

Main Methods:

  • Phase III clinical trials for HSV treatment were initiated in November 2000.
  • The study involved ongoing trials as of September 2001.

Main Results:

  • Resiquimod demonstrated potential in Phase III trials for HSV treatment.
  • Filings for US and European markets were scheduled for 2004.

    • Conclusions:

    • Resiquimod shows promise as a topical immunomodulator for HSV infections.
    • Commercial launch with Eli Lilly was anticipated between 2004 and 2005.